Stay updated on Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.

Latest updates to the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page
- Check5 days agoChange DetectedThis update changes the site’s visible revision/version indicator from v3.5.2 to v3.5.3 without altering the trial’s study details.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. There are no user-facing content changes indicated.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check41 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision updated to v3.4.3; the previous revision v3.4.2 was removed.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision: v3.4.2 has been added; older Revision: v3.4.1 and the government funding notice have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange DetectedSite-wide maintenance notices were added regarding a lapse in government funding and NIH Clinical Center status, and the page revision tag updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.